Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Charles Retina Institute is a world-renowned ophthalmic center specializing in the medical and surgical treatment of vitreoretinal diseases. Founded by Dr. Steve Charles, a pioneer in vitreoretinal surgery and engineering, the institute provides advanced care for complex conditions such as age-related macular degeneration, diabetic retinopathy, and retinal detachments. In addition to its clinical practice, the institute is a premier clinical research site, participating in numerous Phase 1 through Phase 3 clinical trials for novel pharmacotherapies and surgical technologies. The facility serves as a major referral hub and a center for surgical innovation, with its founder having developed many of the instruments and techniques used globally in retinal surgery. The institute is dedicated to advancing the field of ophthalmology through both high-volume patient care and rigorous clinical investigation.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Charles Retina Institute.